Introducing The First Breast Cancer Specific DNA Delivery Reagent:

TransIT®-BrCa Transfection Reagent from Mirus Bio

Madison, WI, March 2013 - Mirus Bio has expanded its transfection expertise with the development of the TransIT®-BrCa Transfection Reagent -a high performance, low toxicity, DNA transfection reagent specifically formulated for breast cancer cell types. This new reagent offers users:

 

  • Superior DNA Delivery - Achieve high expression levels in breast cancer cell types including: MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, T47D.
  • Formulated for Low Cellular Toxicity - Maintain cell density and reduce experimental biases due to toxicity.
  • Scientifically Proven - Developed by Mirus Bio scientists with nearly 2 decades of gene delivery expertise.

Mirus Bio is dedicated to advancing breast cancer research. In addition to providing scientists with state-of-the-art transfection reagents Mirus will donate a portion of every sale to breast cancer research.

Visit www.mirusbio.com for all your transfection needs including data, protocols, technical support or to place an order.

Questions?

Contact Technical Support
8:30AM - 4:00PM CST, M-F
EMAIL - techsupport@mirusbio.com
PHONE - 888.530.0801